share_log

华润双鹤(600062.SH):白消安注射液通过仿制药质量和疗效一致性评价

China resources double-crane pharmaceutical (600062.SH): The consistency evaluation of generic drug quality and efficacy of Bixiaoan injection has been passed.

Gelonghui Finance ·  Sep 5 05:00

China Resources Double-Crane (600062.SH) announced that the company has received the National Medical Products Administration's approval notice for the supplementary application of Bai Xiao An Injection (referred to as "the pharmaceutical") (Notice Number: 2024B04014). Bai Xiao An Injection is used in combination with cyclophosphamide as a pre-transplant conditioning regimen for allogeneic hematopoietic stem cell transplantation in chronic myelogenous leukemia.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment